Brian Bryzinski

739 total citations
15 papers, 483 citations indexed

About

Brian Bryzinski is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Brian Bryzinski has authored 15 papers receiving a total of 483 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Surgery, 8 papers in Endocrinology, Diabetes and Metabolism and 7 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Brian Bryzinski's work include Diabetes Treatment and Management (6 papers), Blood Pressure and Hypertension Studies (4 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (3 papers). Brian Bryzinski is often cited by papers focused on Diabetes Treatment and Management (6 papers), Blood Pressure and Hypertension Studies (4 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (3 papers). Brian Bryzinski collaborates with scholars based in United States, United Kingdom and Australia. Brian Bryzinski's co-authors include Maciej Adamczyk, Valerie A. Cain, Peter H. Jones, James W. Blasetto, James M. McKenney, W.J. Elliott, Henry R. Black, Michael A. Weber, Jennifer McElhattan and Harold Bays and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and The American Journal of Cardiology.

In The Last Decade

Brian Bryzinski

15 papers receiving 458 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brian Bryzinski United States 9 262 236 117 97 43 15 483
DN O'Neal Australia 10 160 0.6× 151 0.6× 291 2.5× 28 0.3× 25 0.6× 17 436
Markus Schwertfeger Germany 9 166 0.6× 155 0.7× 43 0.4× 19 0.2× 11 0.3× 22 391
Cristina Varas Spain 6 89 0.3× 137 0.6× 203 1.7× 34 0.4× 9 0.2× 10 427
Keon‐Woong Moon South Korea 13 289 1.1× 327 1.4× 58 0.5× 32 0.3× 22 0.5× 50 522
Gerald Klose Germany 13 222 0.8× 130 0.6× 218 1.9× 37 0.4× 44 1.0× 43 547
Naozumi Kubota Japan 14 174 0.7× 297 1.3× 128 1.1× 15 0.2× 11 0.3× 36 484
Monique T. Mulder Netherlands 17 330 1.3× 184 0.8× 173 1.5× 19 0.2× 119 2.8× 44 712
Rita Samuel United States 14 353 1.3× 254 1.1× 220 1.9× 132 1.4× 41 1.0× 41 561
Richard M. Moe United States 5 307 1.2× 111 0.5× 181 1.5× 92 0.9× 57 1.3× 6 447

Countries citing papers authored by Brian Bryzinski

Since Specialization
Citations

This map shows the geographic impact of Brian Bryzinski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Bryzinski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Bryzinski more than expected).

Fields of papers citing papers by Brian Bryzinski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Bryzinski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Bryzinski. The network helps show where Brian Bryzinski may publish in the future.

Co-authorship network of co-authors of Brian Bryzinski

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Bryzinski. A scholar is included among the top collaborators of Brian Bryzinski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Bryzinski. Brian Bryzinski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Bonora, Enzo, Brian Bryzinski, Boaz Hirshberg, & W. James Cook. (2015). A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score. Nutrition Metabolism and Cardiovascular Diseases. 26(5). 374–379. 1 indexed citations
2.
3.
Bryzinski, Brian, Elsie Allen, W. James Cook, & Boaz Hirshberg. (2014). Saxagliptin efficacy and safety in patients with type 2 diabetes receiving concomitant statin therapy. Journal of Diabetes and its Complications. 28(6). 887–893. 2 indexed citations
4.
5.
Bays, Harold, Jennifer McElhattan, & Brian Bryzinski. (2007). A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus. Diabetes and Vascular Disease Research. 4(3). 181–193. 37 indexed citations
6.
7.
McKenney, James M., Peter H. Jones, Maciej Adamczyk, et al.. (2003). Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Current Medical Research and Opinion. 19(8). 689–698. 133 indexed citations
8.
Warwick, Mike J., et al.. (1999). Design of a phase II efficacy trial for a GPIIb/IIIa antagonist using computer simulation. Clinical Pharmacology & Therapeutics. 65(2). 182–182. 1 indexed citations
9.
Ferguson, J J, et al.. (1998). Sustained platelet GP IIb/IIIa blockade with oral orbofiban: interim phamacodynamic results of the SOAR study. Journal of the American College of Cardiology. 31. 185–185. 10 indexed citations
10.
11.
Deedwania, Prakash, et al.. (1998). Sustained platelet GP IIb/IIIa blockade with oral orbofiban: interim safety and tolerability results of the SOAR study. Journal of the American College of Cardiology. 31. 94–94. 2 indexed citations
12.
Kereiakes, Dean J., Neal S. Kleiman, James J. Ferguson, et al.. (1998). Pharmacodynamic Efficacy, Clinical Safety, and Outcomes After Prolonged Platelet Glycoprotein IIb/IIIa Receptor Blockade With Oral Xemilofiban. Circulation. 98(13). 1268–1278. 81 indexed citations
13.
Frishman, William H., et al.. (1995). First‐Line Therapy Option with Low‐Dose Bisoprolol Fumarate and Low‐Dose Hydrochlorothiazide in Patients with Stage I and Stage II Systemic Hypertension. The Journal of Clinical Pharmacology. 35(2). 182–188. 41 indexed citations
14.
Davidov, Michael, Sant P. Singh, Nicolas D. Vlachakis, et al.. (1994). Bisoprolol, a once‐a‐day beta‐blocking agent for patients with mild to moderate hypertension. Clinical Cardiology. 17(5). 263–268. 15 indexed citations
15.
Carr, Albert A., et al.. (1990). Multicenter Evaluation of the Hemodynamic Effects of Bisoprolol in Patients with Mild to Moderate Hypertension. The Journal of Clinical Pharmacology. 30(12). 1096–1101. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by DN O'Neal Breakdown of academic impact, for papers by Markus Schwertfeger Breakdown of academic impact, for papers by Cristina Varas Breakdown of academic impact, for papers by Keon‐Woong Moon Breakdown of academic impact, for papers by Gerald Klose Breakdown of academic impact, for papers by Naozumi Kubota Breakdown of academic impact, for papers by Monique T. Mulder Breakdown of academic impact, for papers by Rita Samuel Breakdown of academic impact, for papers by Richard M. Moe
Rankless by CCL
2026